Has Novavax Lost the Vaccine Race to Moderna?
In December, the Food and Drug Administration (FDA) gave emergency use authorizations (EUA) to the mRNA vaccines from Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). Since then, the two companies have seized the lion share of the vaccine market in the U.S.
Meanwhile, the Novavax (NASDAQ: NVAX) vaccine has been delayed, and the company now hopes that it will receive an EUA in July. Will there be any vaccine market left for the biotech upstart? In this clip from Motley Fool Live recorded on May 14, 2021, Healthcare and Cannabis Bureau Chief Corinne Cardina and Motley Fool writer Taylor Carmichael discuss whether Moderna has squashed Novavax.
Source Fool.com
